SRS Capital Advisors Inc. Raises Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

SRS Capital Advisors Inc. lifted its position in shares of Stevanato Group S.p.A. (NYSE:STVN) by 327.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,593 shares of the company’s stock after acquiring an additional 1,220 shares during the quarter. SRS Capital Advisors Inc.’s holdings in Stevanato Group were worth $43,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Natixis Advisors L.P. increased its position in Stevanato Group by 1.9% during the 4th quarter. Natixis Advisors L.P. now owns 23,858 shares of the company’s stock worth $651,000 after purchasing an additional 449 shares in the last quarter. First Horizon Advisors Inc. increased its stake in Stevanato Group by 14.1% during the 4th quarter. First Horizon Advisors Inc. now owns 5,311 shares of the company’s stock worth $145,000 after buying an additional 657 shares during the period. Fifth Third Bancorp boosted its stake in Stevanato Group by 70.1% during the 3rd quarter. Fifth Third Bancorp now owns 2,473 shares of the company’s stock valued at $73,000 after acquiring an additional 1,019 shares during the last quarter. Calamos Wealth Management LLC boosted its holdings in Stevanato Group by 3.3% in the fourth quarter. Calamos Wealth Management LLC now owns 50,585 shares of the company’s stock worth $1,380,000 after purchasing an additional 1,607 shares during the period. Finally, Raymond James & Associates grew its holdings in shares of Stevanato Group by 0.9% during the third quarter. Raymond James & Associates now owns 197,316 shares of the company’s stock valued at $5,864,000 after purchasing an additional 1,806 shares during the last quarter.

Stevanato Group Stock Down 1.3 %

Shares of NYSE STVN opened at €26.45 ($28.44) on Friday. Stevanato Group S.p.A. has a 1-year low of €23.00 ($24.73) and a 1-year high of €36.30 ($39.03). The company has a quick ratio of 1.06, a current ratio of 1.50 and a debt-to-equity ratio of 0.23. The company has a fifty day moving average price of €29.63 and a 200 day moving average price of €29.20.

Stevanato Group (NYSE:STVN) last released its earnings results on Thursday, March 7th. The company reported €0.18 ($0.19) EPS for the quarter, missing analysts’ consensus estimates of €0.19 ($0.20) by (€0.01) (($0.01)). The business had revenue of €320.60 million for the quarter, compared to the consensus estimate of €326.85 million. Stevanato Group had a return on equity of 14.31% and a net margin of 13.43%. The company’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.19 earnings per share. As a group, equities analysts expect that Stevanato Group S.p.A. will post 0.67 EPS for the current year.

Wall Street Analysts Forecast Growth

STVN has been the subject of several research reports. BNP Paribas initiated coverage on Stevanato Group in a research note on Monday, April 22nd. They set an “outperform” rating for the company. Morgan Stanley restated an “equal weight” rating and set a $30.00 price target on shares of Stevanato Group in a report on Monday, April 22nd. Finally, Stephens reiterated an “overweight” rating and issued a $38.00 price objective on shares of Stevanato Group in a research note on Monday, March 25th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of €33.63 ($36.16).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.